IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC Trademark

Trademark Overview

On Thursday, April 12, 2012, a trademark application was filed for IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC with the United States Patent and Trademark Office. The USPTO has given the IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC trademark a serial number of 85595704. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 25, 2020. This trademark is owned by Bristol-Myers Squibb Company. The IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Product research and development; conducting clinical trials relating to pharmaceutical preparations for human use
ideate ipilimumab drug evaluation immunotherapy in squamous nsclc

General Information

Serial Number85595704
Word MarkIDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC
Filing DateThursday, April 12, 2012
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 25, 2020
Registration Number4485747
Registration DateTuesday, February 18, 2014
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 19, 2013

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"IPILIMUMAB DRUG EVALUATION" AND "IMMUNOTHERAPY IN SQUAMOUS NSCLC"
Description of MarkThe mark consists of the words "IDEATE IPILIMUMAB DRUG EVALUATION" in stylized letters above an oblong containing the words "IMMUNOTHERAPY IN SQUAMOUS NSCLC", all against stylized chromosomes and a stylized DNA strand.
Goods and ServicesProduct research and development; conducting clinical trials relating to pharmaceutical preparations for human use

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 25, 2020
Primary Code042
First Use Anywhere DateFriday, May 31, 2013
First Use In Commerce DateFriday, May 31, 2013

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016
Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10154
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Friday, September 25, 2020CANCELLED SEC. 8 (6-YR)
Monday, February 18, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, October 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 21, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 21, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 18, 2014REGISTERED-PRINCIPAL REGISTER
Saturday, January 11, 2014NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, January 10, 2014LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, January 10, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 9, 2014ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, January 9, 2014STATEMENT OF USE PROCESSING COMPLETE
Thursday, November 7, 2013USE AMENDMENT FILED
Thursday, January 9, 2014EXTENSION 1 GRANTED
Thursday, November 7, 2013EXTENSION 1 FILED
Tuesday, December 31, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 10, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, November 7, 2013TEAS EXTENSION RECEIVED
Thursday, November 7, 2013TEAS STATEMENT OF USE RECEIVED
Wednesday, July 3, 2013ASSIGNED TO EXAMINER
Tuesday, May 14, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 19, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2013PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 27, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, February 8, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, February 7, 2013ASSIGNED TO LIE
Sunday, January 27, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 2, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 2, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 2, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 6, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 6, 2012NON-FINAL ACTION E-MAILED
Friday, July 6, 2012NON-FINAL ACTION WRITTEN
Friday, June 29, 2012ASSIGNED TO EXAMINER
Friday, April 20, 2012NOTICE OF DESIGN SEARCH CODE MAILED
Thursday, April 19, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 17, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

squamous nsclc immunotherapy evaluation ipilimumab drug ideate relating pharmaceutical preparations human trials clinical research development conducting product